Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)
Kenneth Blum, Eric R Braverman, Milan Makale, et al.
Journal of Addiction Psychiatry
|
September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and Present
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)
Kenneth Blum, Eric R Braverman, Milan Makale, et al.
Journal of Addiction Psychiatry
|
September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and Present
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Page
of 7